Background and Objectives: A randomized, double-blind clinical trial was conducted based on the CONSORT study protocol for randomized clinical trials (NCT06531720) to compare the effectiveness of oral mucosa healing properties of 0.2% chlorhexidine digluconate (CHX) and 8.7% choline salicylate (CHS), as well as a control group (CON) with no intervention, in patients with delivered partial removable dentures (PRDs). Materials and Methods: Patients (n = 27) who were enrolled in the study were healthy subjects according to the inclusion/exclusion criteria, and they received new PRDs to complement Kennedy’s class III and IV deficiencies. During the process of adaptation to new prosthetic restorations, OMLs were formed and treated with one of two selected preparations, either CHX = 0.2% or CHS = 8.7%, in relation to the control group (CON). The wound surface area (WSA) (mm²) was measured on repeatable intraoral images taken in accordance with the examination protocol on the first control visit on day 1, day 3, day 7, day 10, and day 14 with the assistance of computer software. Results: There were no statistically significant differences between groups. The fastest effect of WSA complete reduction was observed in the CHX group after 7 days (WAS = 0.78, SD = 1.18) in comparison to CHS = 10 days (WAS = 0.44, SD = 0.90) and CON = 14 days (WAS = 0.22, SD = 0.67). The decrease in the WSA after 7 days of observation was 85.1% in the CHX group, 70.1% in the CHS group, and 59.2% in the CON group. Conclusions: The WSA decreased most rapidly after 7 days of treatment with 0.2% chlorhexidine digluconate (CHX), slightly more slowly after 10 days of treatment with 8.7% choline salicylate (CHS), and relatively most slowly in the CON group, who were not treated with any topical medication after 14 days. Oral mucosa lesions (OMLs) therapy during the process of adaptation to new removable prosthetic restorations is a very important element supporting the whole process. Topical medications containing 0.2% chlorhexidine digluconate are indicated as adjunctive therapy in the process of the supportive treatment and disinfection of oral mucosa lesions. However, this does not release the dentist from liability for the careful adjustment of the removable prosthetic restoration.

Bruxism-induced wear and microbial colonization of oral splints remain significant challenges in restorative dentistry. In this study, we developed a series of antibacterial nanocomposites based on a poly(ethylene terephthalate-co-1,4-cyclohexanedimethylene terephthalate) (PET-G) matrix incorporated with zinc oxide (ZnO) particles (3, 7, and 10 wt%), designed for the next generation of oral appliances. The composites were fabricated via a solvent-casting method followed by thermal processing. Differential scanning calorimetry (DSC) revealed that the amorphous nature and glass transition temperature (Tg ≈ 80 °C) of the PET-G matrix remained stable, ensuring excellent processability. While a minor decrease in Shore D hardness and flexural strength (up to 15%) was observed due to filler-induced structural discontinuity, the mechanical integrity remained within clinically acceptable limits. Crucially, the PET-G/ZnO composites exhibited potent antimicrobial activity; the 7 and 10 wt% loadings achieved a 100% reduction in Streptococcus oralis viability and significant inhibition of Candida albicans. These findings demonstrate that ZnO integration provides a dual-functional advantage—maintaining the thermoplastic versatility of PET-G while introducing critical bioactive properties, positioning these materials as a superior alternative for effective long-term bruxism therapy.

Cranio-mandibular disorders can affect people of all ages. The presence or absence of teeth does not determine the occurrence of parafunctions such as bruxism. With age, degenerative changes are more common in the aetiology of temporomandibular disorders. Particularly in edentulous patients, it...